Printer Friendly

Precipio, Nucleai partner to develop AI-powered hemepath solution.

Precipio announced an agreement with Israel-based artificial intelligence pathology platform company Nucleai who specializes in applying Machine Learning and Machine Vision algorithms to pathology domain. Nucleai's experienced team has adapted artificial intelligence technology previously used for satellite image analysis to the detection of cancer using biopsy image analysis to distinguish between abnormal, potentially malignant cells and normal cells. Nucleai's platform assists pathologists during their morphologic assessment of a biopsy with a pre-scan of slides to identify areas of potential abnormality, reducing scanning time and improving accuracy by allowing the pathologist to focus on areas of interest. Nucleai has initially developed solutions for prostate, breast and gastrointestinal related diseases. The partnership with Precipio, with its focus on Hematopathology, will allow Nucleai to expand its product offering. Precipio will contribute the expertise of its world leading academic pathology team, as well as its laboratory workup, through its partnerships with specialized, academic-level medical school pathology departments. The collaboration will assist the adaptation of the platform to the identification of abnormalities during the morphologic assessment of hematopoietic, or blood-related malignancies.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jun 26, 2018
Previous Article:Atossa Genetics opens Phase 2 study of topical endoxifen to treat MBD.
Next Article:Walgreens' PL personal care products priced better than Amazon's, says Jefferies.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters